Primary objective: To investigate the biodistribution, radiation dosimetry, and
pharmacokinetics of two separate intravenous (IV) injections of Xofigo (100 kBq/kg body
weight [b.w.] [=110 kBq/kg based on the 2015 National Institute of Standards and Technology
standardization], 6 weeks apart).
Secondary objectives: To determine the safety of IV injections of Xofigo after two separate
injections (6 weeks apart), to evaluate treatment response (antitumour effect in osteoblastic
bone metastases) of Xofigo treatment consisting of two injections of activity 100 kBq/kg b.w.
(=110 kBq/kg based on the 2015 National Institute of Standards and Technology
standardization), 6 weeks apart and to evaluate long term radiation toxicity and to collect
survival data at 6 and 12 months after the first injection